GlassScriptPhysician profile
Hong-Yiou Lin
NPI 1659781433
$3,127.29
in general payments reported to CMS, 2019-2025
23 companies · $801 in 2025
The $801 reported for 2025 was more than what 81% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $211 · 2023: $793 · 2024: $1,322 · 2025: $801.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,391 · Consulting Fee: $525.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,391.45 |
| Consulting Fee | $525.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,076.58 | 2023-2025 | Imfinzi, Enhertu, Lynparza |
| Merck Sharp & Dohme LLC | $283.97 | 2023-2025 | Keytruda, Welireg, Keytruda Qlex |
| Eisai INC. | $245.84 | 2023-2025 | |
| Seagen INC. | $229.74 | 2022-2023 | Padcev |
| Bayer Healthcare Pharmaceuticals INC. | $226.19 | 2023-2025 | |
| Exelixis INC. | $185.69 | 2022-2023 | Cabometyx |
| Bioprotect Medical, INC. | $146.89 | 2025 | Bioprotect Balloon Implant System |
| Gilead Sciences, INC. | $124.37 | 2022-2024 | |
| Boston Scientific Corporation | $71.84 | 2024-2025 | Spaceoar System, Spaceoar Vue System - 10ml |
| Sobi, INC | $57.95 | 2024-2025 | |
| Beigene USA, INC. | $57.13 | 2024 | Brukinsa |
| Incyte Corporation | $51.27 | 2022-2023 | Jakafi |
| E.R. Squibb & Sons, L.L.C. | $50.70 | 2023 | Opdivo |
| Karyopharm Therapeutics INC. | $48.97 | 2025 | Xpovio |
| Takeda Pharmaceuticals U.S.A., INC. | $34.99 | 2023 | Fruzaqla |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $34.70 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $33.64 | 2024 | Libtayo |
| Janssen Biotech, INC. | $32.66 | 2025 | Rybrevant |
| Blue Earth Diagnostics | $29.96 | 2025 | Posluma |
| Geron Corporation | $29.96 | 2024 | Rytelo |
| Servier Pharmaceuticals LLC | $24.98 | 2025 | |
| Cti Biopharma Corp. | $24.97 | 2023 | Vonjo |
| Mirati Therapeutics, INC. | $24.30 | 2024 | Krazati |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hong-Yiou Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.